BDS
TEVA icon

Banco de Sabadell’s Teva Pharmaceuticals TEVA Stock Holding History

Banco de Sabadell’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-6,000
Closed -$74K – 381
2020
Q2 		$74K Hold
6,000
– – 0.01% 257
2020
Q1 		$51K Hold
6,000
– – 0.01% 276
2019
Q4 		$59K Hold
6,000
– – 0.01% 292
2019
Q3 		$41K Hold
6,000
– – 0.01% 309
2019
Q2 		$55K Buy
+6,000
New +$72.3K 0.01% 327

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

Banco de Sabadell's TEVA Position: Q3 2020 in Review

Banco de Sabadell sold out of Teva Pharmaceuticals (TEVA) in Q3 2020, closing a stake of 6,000 shares — an estimated $74K sold.

Banco de Sabadell first reported a position in TEVA in Q2 2019 and held it in 5 quarters. The position peaked at $74K in Q2 2020. 443 funds tracked by Wall St. Rank hold TEVA as of Q3 2020.

  • Banco de Sabadell reported no remaining Teva Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • Banco de Sabadell sold 6,000 Teva Pharmaceuticals shares in Q3 2020, an estimated $74K.
  • Banco de Sabadell first reported a position in Teva Pharmaceuticals in Q2 2019 and held it in 5 quarters.
  • Banco de Sabadell's Teva Pharmaceuticals position peaked at $74K in Q2 2020.
  • 443 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2020.

Based on Banco de Sabadell's 13F filing for Q3 2020, filed 13 Nov 2020.